E Watertown, Massachusetts Clinical Trials

A listing of E Watertown, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 128 clinical trials
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy …

solid tumor
Massachusetts General Hospital PHASE 1 (recruiting) & PHASE 2 (recruiting)
 (6.0 away) Contact site
  • 05 Feb, 2021
  • +131 other locations
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.

measurable disease
neutrophil count
Dana Farber Cancer Center
 (6.3 away) Contact site
  • 29 Jan, 2021
  • +29 other locations
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) …

janus kinase inhibitor
growth factor
myelodysplastic syndromes
Massachusetts General Hospital
 (6.0 away) Contact site
  • 04 Feb, 2021
  • +58 other locations
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety …

Research Site
 (4.5 away) Contact site
  • 26 Jul, 2021
  • +24 other locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 10 combination therapies in 11 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide …

line of therapy
immunomodulatory imide drug
Dana Farber Cancer Institute
 (4.5 away) Contact site
  • 07 May, 2021
  • +23 other locations
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom …

t-cell lymphoma
solid tumour
neutrophil count
Dana-Farber Cancer Institute
 (4.5 away) Contact site
  • 05 Apr, 2021
  • +83 other locations
A Study of LOXO-292 in Participants With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

solid tumour
ret inhibitor
Dana Farber Cancer Institute
 (4.5 away) Contact site
  • 23 Jul, 2021
  • +159 other locations
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations …

solid tumour
major surgery
lung carcinoma
cancer chemotherapy
Dana Farber Cancer Institute
 (4.5 away) Contact site
  • 29 May, 2021
  • +94 other locations
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study …

solid tumor
kidney function tests
primary tumor
experimental drug
Dana-Farber Cancer Institute
 (4.5 away) Contact site
  • 27 Jul, 2021
  • +78 other locations
Study of RP-3500 in Advanced Solid Tumors

The primary purpose of this study is to study the maximum tolerated dose (MTD) of orally-administered RP-3500 alone or in combination with talazoparib, a PARP inhibitor, in patients with advanced solid tumors with ATR inhibitor-sensitizing mutations. This study will also evaluate the safety and tolerability of RP-3500 alone or in …

Dana-Farber Cancer Institute
 (4.5 away) Contact site
  • 19 May, 2021
  • +14 other locations